The Midwest's largest drugmaker isn't finished making mid-sized deals.
News & Analysis: Dermira
The Super Bowl of healthcare kicked off early for these companies.
It looks like Eli Lilly will compete with Sanofi and Regeneron in the lucrative eczema arena.
Investors are thrilled with the FDA's decision to grant its eczema drug a speedy review.
The demise of a potential competitor gave Dermira investors a reason to cheer.
The company gave investors a closer look at its eczema candidate and they liked what they saw.
DERM earnings call for the period ending March 31, 2019.
Results from a mid-stage study with a potential new eczema drug gave investors a reason to cheer.
An analyst's upgrade provides another boost to the high-flying biotech stock.
The skincare specialist's experimental eczema treatment hit the mark in mid-stage testing, but what about the road ahead?